Home Other Building Blocks 100986-86-5
100986-86-5,MFCD00869643
Catalog No.:AA0003AX
100986-86-5 | (R)-Ofloxacin
Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
98%
2 weeks  
$569.00   $399.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Q & A
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA0003AX
Chemical Name:
(R)-Ofloxacin
CAS Number:
100986-86-5
Molecular Formula:
C18H20FN3O4
Molecular Weight:
361.3675
MDL Number:
MFCD00869643
IUPAC Name:
(2R)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
InChI:
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m1/s1
InChI Key:
GSDSWSVVBLHKDQ-SNVBAGLBSA-N
SMILES:
CN1CCN(CC1)c1c(F)cc2c3c1OC[C@H](n3cc(c2=O)C(=O)O)C
UNII:
36OPE0O92Z
Properties
Computed Properties
 
Complexity:
634  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0
Exact Mass:
361.144g/mol
Formal Charge:
0
Heavy Atom Count:
26  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
361.373g/mol
Monoisotopic Mass:
361.144g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
73.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-0.4  

Synonyms
 
(R)-Ofloxacin 
100986-86-5 
DR-3354 
EN300-71971 
CCRIS 4073 
(2R)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid 
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3R)- 
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3R)- 
rofloxacin 
(R)-Levofloxacin 
NCGC00016948-01 
(R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid 
D-Ofloxacin 
(+)-Ofloxacin 
CAS-82419-36-1 
d-isomer of ofloxacin 
(R)-(+)-Ofloxacin 
AC1L9QHV 
Lopac-O-8757 
AC1Q29EB 
fluoro-methyl-(4-methylpiperazin-1-yl)-oxo-[?]carboxylic acid 
MLS006011975 
CHEMBL420937 
d-Levofloxacin 
SCHEMBL4316947 
DTXSID1058715 
CTK0H6481 
HY-B0330D 
HMS3655N03 
ZINC537891 
(2R)-7-Fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0(5,13)]trideca-5(13),6,8,11-tetraene-11-carboxylic acid 
BDBM50226409 
EiM17-02662 
AKOS030254688 
R-Ofloxacin 
DB03034 
MCULE-6007235957 
NE36894 
NCGC00015772-01 
SMR004703538 
CS-0089617 
FT-0673216 
SW219935-1 
J-000297 
Z1259192072 
DEXTROFLOXACINE 
UNII-A4P49JAZ9H component GSDSWSVVBLHKDQ-SNVBAGLBSA-N 
(+)-(R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benz 
(2R)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0?,??]trideca-5(13),6,8,11-tetraene-11-carboxylic acid 
(R)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid 
Oftaquix 
LEVOFLOXACIN 
Ofloxacin, D- 
Levofloxacin (Levaquin) 
CID452723 
82419-36-1 
UNII-36OPE0O92Z 
XED 
DR 3354 
R-(+)-Ofloxacin 
36OPE0O92Z 
Literature

Title: Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.

Journal: Antimicrobial agents and chemotherapy 19961101

Title: In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis.

Journal: Antimicrobial agents and chemotherapy 19960701

Title: Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1-mediated cytotoxicity.

Journal: Cell structure and function 19901001

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Additional Info:
Q & A